Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer
In human medicine, the progression from early neoplasia development to either complete resolution of tumorigenesis and associated inflammation or chronicity and fatal outcomes remain difficult to predict. Resolution of inflammation is an active process that stimulates the termination of the inflamma...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/12/6473 |
| _version_ | 1797486581006729216 |
|---|---|
| author | Domenico Mattoscio Giulia Ferri Claudia Miccolo Susanna Chiocca Mario Romano Antonio Recchiuti |
| author_facet | Domenico Mattoscio Giulia Ferri Claudia Miccolo Susanna Chiocca Mario Romano Antonio Recchiuti |
| author_sort | Domenico Mattoscio |
| collection | DOAJ |
| description | In human medicine, the progression from early neoplasia development to either complete resolution of tumorigenesis and associated inflammation or chronicity and fatal outcomes remain difficult to predict. Resolution of inflammation is an active process that stimulates the termination of the inflammatory response and promotes return to homeostasis, while failure in resolution contributes to the development of a number of diseases. To understand how resolution pathways contribute to tumorigenesis, we defined and employed a cumulative score based on the expression level of genes involved in synthesis, signaling, and metabolism of the D-series resolvin (RvD). This score was used for comparative analyses of clinical, cellular, and molecular features of tumors, based on RNA-sequencing (RNA-seq) datasets collected within The Cancer Genome Atlas (TCGA) program. Our results indicate that higher RvD scores are associated with better clinical outcome of patients with head and neck squamous cell carcinoma (HNSC), and with molecular and cellular signatures indicative of enhanced anti-tumor immunity and better response to immune-checkpoint inhibitors (ICI), also in human papilloma virus (HPV) negative HNSC subtypes. Thus, higher activity of the RvD pathway identifies patients with improved resolution and a more efficient immune reaction against cancer. |
| first_indexed | 2024-03-09T23:36:11Z |
| format | Article |
| id | doaj.art-9176604ad0af41ed8cb40cea15679b14 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T23:36:11Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9176604ad0af41ed8cb40cea15679b142023-11-23T17:01:21ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-06-012312647310.3390/ijms23126473Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck CancerDomenico Mattoscio0Giulia Ferri1Claudia Miccolo2Susanna Chiocca3Mario Romano4Antonio Recchiuti5Department of Medical, Oral, and Biotechnology Science, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral, and Biotechnology Science, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, ItalyDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, ItalyDepartment of Medical, Oral, and Biotechnology Science, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, ItalyDepartment of Medical, Oral, and Biotechnology Science, University “G. d’Annunzio” Chieti-Pescara, 66100 Chieti, ItalyIn human medicine, the progression from early neoplasia development to either complete resolution of tumorigenesis and associated inflammation or chronicity and fatal outcomes remain difficult to predict. Resolution of inflammation is an active process that stimulates the termination of the inflammatory response and promotes return to homeostasis, while failure in resolution contributes to the development of a number of diseases. To understand how resolution pathways contribute to tumorigenesis, we defined and employed a cumulative score based on the expression level of genes involved in synthesis, signaling, and metabolism of the D-series resolvin (RvD). This score was used for comparative analyses of clinical, cellular, and molecular features of tumors, based on RNA-sequencing (RNA-seq) datasets collected within The Cancer Genome Atlas (TCGA) program. Our results indicate that higher RvD scores are associated with better clinical outcome of patients with head and neck squamous cell carcinoma (HNSC), and with molecular and cellular signatures indicative of enhanced anti-tumor immunity and better response to immune-checkpoint inhibitors (ICI), also in human papilloma virus (HPV) negative HNSC subtypes. Thus, higher activity of the RvD pathway identifies patients with improved resolution and a more efficient immune reaction against cancer.https://www.mdpi.com/1422-0067/23/12/6473head and neck cancerresolution of inflammationresolvin Dhuman papilloma virus (HPV)pro-resolving lipid mediatorscancer immunotherapy |
| spellingShingle | Domenico Mattoscio Giulia Ferri Claudia Miccolo Susanna Chiocca Mario Romano Antonio Recchiuti Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer International Journal of Molecular Sciences head and neck cancer resolution of inflammation resolvin D human papilloma virus (HPV) pro-resolving lipid mediators cancer immunotherapy |
| title | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer |
| title_full | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer |
| title_fullStr | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer |
| title_full_unstemmed | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer |
| title_short | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer |
| title_sort | gene expression of the d series resolvin pathway predicts activation of anti tumor immunity and clinical outcomes in head and neck cancer |
| topic | head and neck cancer resolution of inflammation resolvin D human papilloma virus (HPV) pro-resolving lipid mediators cancer immunotherapy |
| url | https://www.mdpi.com/1422-0067/23/12/6473 |
| work_keys_str_mv | AT domenicomattoscio geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer AT giuliaferri geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer AT claudiamiccolo geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer AT susannachiocca geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer AT marioromano geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer AT antoniorecchiuti geneexpressionofthedseriesresolvinpathwaypredictsactivationofantitumorimmunityandclinicaloutcomesinheadandneckcancer |